Gut microbiota and host Cyp450s co-contribute to pharmacokinetic variability in mice with non-alcoholic steatohepatitis: Effects vary from drug to drug

Porayette, 2014, One size fits one: pharmacogenetics in gastroenterology, Clin Gastroenterol Hepatol, 12, 565, 10.1016/j.cgh.2014.01.035 Lin, 2007, Pharmacokinetic and pharmacodynamic variability: a daunting challenge in drug therapy, Curr Drug Metab, 109, 10.2174/138920007779816002 Sun, 2019, Influence factors of the pharmacokinetics of herbal resourced compounds in clinical practice, Evid Based Complement Alternat Med, 2019, 1 Kulkarni NM, Malampati S, Mahat MY, Chandrasekaran S, Raghul J, Khan AA et al. Altered pharmacokinetics of rosiglitazone in a mouse model of non-alcoholic fatty liver disease. Drug Metab Pers Ther 2016;165–71. doi: 10.1515/dmpt-2016-0008. ter Heine R, Binkhorst L, de Graan AJ, de Bruijn P, Beijnen JH, Mathijssen RH, et al. Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen, Br J Clin Pharmacol. 2014;572-86. doi: 10.1111/bcp.12388. Shu, 2008, Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics, Clin Pharmacol Ther., 83, 273, 10.1038/sj.clpt.6100275 Koukoula M, Dotsikas Y, Molou E, Schulpis KH, Thodi G, Chatzidaki M et al. Study of the effect of CYP2C19 polymorphisms on omeprazole pharmacokinetics by utilizing validated LC-MS/MS and Real Time-PCR methods. J Chromatogr B Analyt Technol Biomed Life Sci. 2017;173–179. doi:10.1016/j.jchromb.2016.06.046. Choi, 2018, The role of gut microbiota in the pharmacokinetics of antihypertensive drugs, Pharmacol Res, 130, 164, 10.1016/j.phrs.2018.01.019 Sommer, 2013, The gut microbiota–masters of host development and physiology, Nat Rev Microbiol, 11, 227, 10.1038/nrmicro2974 Neish, 2021, Preimmune recognition and response to microbial metabolites, Physiology (Bethesda), 36, 94 Sender R, Fuchs S, Milo R. Revised Estimates for the Number of Human and Bacteria Cells in the Body, PLoS Biol 2016;e1002533. doi: 10.1371/journal.pbio.1002533. Zimmermann, 2019, Separating host and microbiome contributions to drug pharmacokinetics and toxicity, Science, 363, 10.1126/science.aat9931 Jarmusch, 2020, Enhanced characterization of drug metabolism and the influence of the intestinal microbiome: a pharmacokinetic, microbiome, and untargeted metabolomics study, Clin Transl Sci, 13, 972, 10.1111/cts.12785 Johnson CH, Patterson AD, Idle JR, Gonzalez FJ. Xenobiotic metabolomics: major impact on the metabolome, Annu Rev Pharmacol Toxicol 2012;37–56. doi: 10.1146/annurev-pharmtox-010611-134748. Jeong, 2013, Role of intestinal microflora in xenobiotic-induced toxicity, Mol Nutr Food Res, 57, 84, 10.1002/mnfr.201200461 Zhang, 2021, The influence of the gut microbiota on the bioavailability of oral drugs, Acta Pharm Sin B, 11, 1789, 10.1016/j.apsb.2020.09.013 Gill, 2006, Metagenomic analysis of the human distal gut microbiome, Science, 312, 1355, 10.1126/science.1124234 Noh, 2017, Impact of gut microbiota on drug metabolism: an update for safe and effective use of drugs, Arch Pharm Res, 40, 1345, 10.1007/s12272-017-0986-y Kang, 2014, Role of metabolism by intestinal microbiota in pharmacokinetics of oral baicalin, Arch Pharm Res, 37, 371, 10.1007/s12272-013-0179-2 Matuskova Z, Anzenbacherova E, Vecera R, Tlaskalova-Hogenova H, Kolar M, Anzenbacher P. Administration of a probiotic can change drug pharmacokinetics: effect of E. coli Nissle 1917 on amidarone absorption in rats, PLoS One. 2014;e87150. doi:10.1371/journal.pone.0087150. Mallory, 2018, Chemical reaction vector embeddings: towards predicting drug metabolism in the human gut microbiome, Pac Symp Biocomput, 56–67 Lindenbaum, 1981, Inactivation of digoxin by the gut flora: reversal by antibiotic therapy, N Engl J Med, 305, 789, 10.1056/NEJM198110013051403 Haiser, 2014, Mechanistic insight into digoxin inactivation by Eggerthella lenta augments our understanding of its pharmacokinetics, Gut Microbes, 5, 233, 10.4161/gmic.27915 Friedman, 2018, Mechanisms of NAFLD development and therapeutic strategies, Nat Med, 24, 908, 10.1038/s41591-018-0104-9 Yue, 2020, Effects of constant light exposure on sphingolipidomics and progression of NASH in high-fat-fed rats, J Gastroenterol Hepatol, 35, 1978, 10.1111/jgh.15005 Reimer, 2020, New drugs for NAFLD: lessons from basic models to the clinic, Hepatol Int, 14, 8, 10.1007/s12072-019-10001-4 Suzuki A, Diehl AM. Nonalcoholic Steatohepatitis, Annu Rev Med.(2017) 85-98. doi:10.1146/annurev-med-051215-031109. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology, Gastroenterology 2012;1592–609. doi: 10.1053/j.gastro.2012.04.001. Jiang, 2019, Inhibiting ceramide synthesis attenuates hepatic steatosis and fibrosis in rats with non-alcoholic fatty liver disease, Front Endocrinol (Lausanne), 665, 10.3389/fendo.2019.00665 Sherif, 2016, Global epidemiology of nonalcoholic fatty liver disease and perspectives on US minority populations, Dig Dis Sci., 61, 1214, 10.1007/s10620-016-4143-0 Zhou J, Zhou F, Wang W, Zhang XJ, Ji YX, Zhang P et al. Epidemiological Features of NAFLD From 1999 to 2018 in China, Hepatology 2020;1851–1864. doi: 10.1002/hep.31150. Chen, 2021, Sirtuin3 rs28365927 functional variant confers to the high risk of non-alcoholic fatty liver disease in Chinese Han population, Lipids Health Dis, 20, 10.1186/s12944-021-01520-x Sumida, 2018, Current and future pharmacological therapies for NAFLD/NASH, J Gastroenterol, 53, 362, 10.1007/s00535-017-1415-1 Konerman, 2018, Pharmacotherapy for NASH: current and emerging, J Hepatol, 68, 362, 10.1016/j.jhep.2017.10.015 Cobbina, 2017, Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters, Drug Metab Rev, 49, 197, 10.1080/03602532.2017.1293683 Machado, 2016, Pathogenesis of nonalcoholic steatohepatitis, Gastroenterology, 150, 1769, 10.1053/j.gastro.2016.02.066 Brandl, 2017, Intestinal microbiota and nonalcoholic steatohepatitis, Curr Opin Gastroenterol, 128, 10.1097/MOG.0000000000000349 Kolodziejczyk, 2019, The role of the microbiome in NAFLD and NASH, EMBO Mol Med, 10.15252/emmm.201809302 Ferslew, 2015, Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis, Clin Pharmacol Ther, 97, 419, 10.1002/cpt.66 Albillos, 2020, The gut-liver axis in liver disease: Pathophysiological basis for therapy, J Hepatol, 72, 558, 10.1016/j.jhep.2019.10.003 Qin, 2014, A high-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spectrometry, Biomed Chromatogr, 28, 197, 10.1002/bmc.3003 Chen, 2003, Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects, Clin Pharmacol Ther, 264, 10.1067/mcp.2003.14 Meyer, 2012, Cytochrome P450 enzymes, Drug Metabol Drug Interact, 1, 10.1515/dmdi-2012-0002 Spaggiari, 2014, Phenotyping of CYP450 in human liver microsomes using the cocktail approach, Anal Bioanal Chem, 406, 4875, 10.1007/s00216-014-7915-4 de Faria Ghetti, 2018, Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis, Eur J Nutr, 57, 861, 10.1007/s00394-017-1524-x Gómez-Lechón, 2009, Cytochrome p450 and steatosis, Curr Drug Metab, 692, 10.2174/138920009789895543 Na, 2018, Investigation of nonalcoholic fatty liver disease-induced drug metabolism by comparative global toxicoproteomics, Toxicol Appl Pharmacol, 352, 28, 10.1016/j.taap.2018.05.021 Li, 2017, In vivo cytochrome P450 activity alterations in diabetic nonalcoholic steatohepatitis mice, J Biochem Mol Toxicol, 31, e21840, 10.1002/jbt.21840 Ye, 2018, Dynamic alterations in the gut microbiota and metabolome during the development of methionine-choline-deficient diet-induced nonalcoholic steatohepatitis, World J Gastroenterol, 24, 2468, 10.3748/wjg.v24.i23.2468 Schneider, 2019, Intestinal microbiota protects against MCD diet-induced steatohepatitis, Int J Mol Sci, 20, 308, 10.3390/ijms20020308 Wang, 2017, Gut microbiota-mediated personalized treatment of hyperlipidemia using berberine, Theranostics, 7, 2443, 10.7150/thno.18290 Mohamed, 2020, Effects of upadacitinib coadministration on the pharmacokinetics of sensitive Cytochrome P450 probe substrates: a study with the modified cooperstown 5+1 cocktail, J Clin Pharmacol, 60, 86, 10.1002/jcph.1496 Sun, 2017, Influence of Shenxiong glucose injection on the activities of Six CYP isozymes and metabolism of warfarin in rats assessed using probe cocktail and pharmacokinetic approaches, Molecules, 22, 1994, 10.3390/molecules22111994 Turpault S, Brian W, Van Horn R, Santoni A, Poitiers F, Donazzolo Y et al. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A, Br J Clin Pharmacol 2009;928–35. doi:10.1111/j.1365-2125.2009.03548.x. Cheng, 2019, Influences of corydalis decumbens on the activities of CYP450 enzymes in rats with a cocktail approach, Biomed Res Int., 2019, 1, 10.1155/2019/1356264 Lin, 2018, Influences of oldenlandia diffusa on the CYP450 activities in rats using a cocktail method by UHPLC-MS/MS, Biochem Res Int, 2018, 1, 10.1155/2018/1467143 Paolini M, Biagi GL, Bauer C, Cantelli-Forti G. Cocktail strategy: complications and limitations, J Clin Pharmacol 1993;1011–2. doi:10.1002/j.1552-4604.1993.tb01936.x. Frye, 1997, Validation of the five-drug “Pittsburgh cocktail” approach for assessment of selective regulation of drug-metabolizing enzymes, Clin Pharmacol Ther, 62, 365, 10.1016/S0009-9236(97)90114-4 Fan L, Zhao X, Tong Q, Zhou X, Chen J, Xiong W et al. Interactions of Dihydromyricetin, a Flavonoid from Vine Tea (Ampelopsis grossedentata) with Gut Microbiota, J Food Sci 2018;1444–1453. doi: 10.1111/1750-3841.14128. Lange ME, Uwiera RRE, Inglis GD. Housing gnotobiotic mice in conventional animal facilities. Curr Protoc Mouse Biol 2019;e59. doi: 10.1002/cpmo.59. Roberts, 2002, Enterohepatic circulation: physiological, pharmacokinetic and clinical implications, Clin Pharmacokinet, 41, 751, 10.2165/00003088-200241100-00005 Orme, 1990, Factors affecting the enterohepatic circulation of oral contraceptive steroids, Am J Obstet Gynecol, 163, 2146, 10.1016/0002-9378(90)90555-L Byrne CD, Targher G. NAFLD: a multisystem disease, J Hepatol 2015;S47-64. doi: 10.1016/j.jhep.2014.12.012.